publication date: Nov. 30, 2018
Conversation with The Cancer Letter
Hyman: “This approval adds to the growing utility of sequencing in patients with cancer”
Chief, Early Drug Development Service,
Memorial Sloan Kettering Cancer Center
Global principal investigator for a larotrectinib clinical trial.
As Vitrakvi (larotrectinib) becomes the second drug to get FDA approval for a site-agnostic indication, physicians will have yet another reason to order sequencing, said David Hyman, chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center and the principal investigator for a larotrectinib clinical trial that led to the approval.
“As we speak, more than ten solid tumors now require some form of routine sequencing to guide the standard of care. I expect this trend to continue and the detection of TRK fusion-positive cancers will mirror the adoption of NGS testing primarily driven by clinical needs other than TRK detection, rather than guiding other standard therapy prescribing for these patients,” Hyman said.
Hyman spoke with Paul Goldberg, editor and publisher of The Cancer Letter.
This is really cool science, and it’s great to see that such things are possible, but this indication affects a very small proportion of cancer patients, and given that, what is the significance of this approval?
This is an important question. It is true that the number of … Continue reading Hyman: “This approval adds to the growing utility of sequencing in patients with cancer”
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.